This CME series focuses on improving the overall management of patients with GI disease. Faculty experts provide education that is designed to strengthen clinician skill-sets needed to provide not only better patient care —via enhanced diagnosis and management strategies—but also to optimize patient outcomes through strategies that are meant to improve therapeutic adherence.
Practice Changing Highlights in G/GEJ Cancers: The Latest Data from Chicago
Practice Changing Highlights in G/GEJ Cancers: The Latest Data from Chicago
Optimizing Treatment of Metastatic G/GEJ Cancers: Balancing Efficacy and Adverse Effects With Combination Regimens
Optimizing Treatment of Metastatic G/GEJ Cancers: Balancing Efficacy and Adverse Effects With Combination Regimens
Navigating Treatment Paths: Selection and Sequencing in Biomarker-Driven Combination Regimens for First-Line G/GEJ Cancer Therapy
Navigating Treatment Paths: Selection and Sequencing in Biomarker-Driven Combination Regimens for First-Line G/GEJ Cancer Therapy
How Can a Multidisciplinary Team Optimize Management of G/GEJ Cancer–Related Symptom Burden?
How Can a Multidisciplinary Team Optimize Management of G/GEJ Cancer–Related Symptom Burden?
Integrating Clinical Insights: Key G/GEJ Cancer Data Analyzed from the San Diego Oncology Conference
Integrating Clinical Insights: Key G/GEJ Cancer Data Analyzed from the San Diego Oncology Conference
What Is the Current Standard for First-Line Treatment of Metastatic HER2-Positive G/GEJ Cancers?
What Is the Current Standard for First-Line Treatment of Metastatic HER2-Positive G/GEJ Cancers?
What Is the Current Standard for First-Line Treatment of Metastatic HER2-Negative G/GEJ Cancers?
What Is the Current Standard for First-Line Treatment of Metastatic HER2-Negative G/GEJ Cancers?
HER2 & PD-L1: Exploring Clinical Characteristics of G/GEJ Cancers in Relation to Biomarker Positivity
HER2 & PD-L1: Exploring Clinical Characteristics of G/GEJ Cancers in Relation to Biomarker Positivity
Claudin18.2: An Emerging Biomarker and Its Significance as a Therapeutic Target in G/GEJ Cancers
Claudin18.2: An Emerging Biomarker and Its Significance as a Therapeutic Target in G/GEJ Cancers
Incorporating Data Into Practice: Late-Breaking Highlights on G/GEJ Cancers From the 2024 GI Congress
Incorporating Data Into Practice: Late-Breaking Highlights on G/GEJ Cancers From the 2024 GI Congress
What Is the Evidence Supporting CLDN18.2 Targeting in Frontline Management of G/GEJ Cancers
What Is the Evidence Supporting CLDN18.2 Targeting in Frontline Management of G/GEJ Cancers
